About Assembly Biosciences (NASDAQ:ASMB)
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:ASMB
- CUSIP: 92282210
- Web: www.assemblybio.com
Capitalization:- Market Cap: $542.45 million
- Outstanding Shares: 17,364,000
Average Prices:- 50 Day Moving Avg: $31.63
- 200 Day Moving Avg: $25.43
- 52 Week Range: $10.93 - $36.31
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $3.04 million
- Price / Sales: 178.44
- Book Value: $3.26 per share
- Price / Book: 9.58
Profitability:- EBITDA: ($50,920,000.00)
- Return on Equity: -68.84%
- Return on Assets: -43.64%
Debt:- Current Ratio: 6.48%
- Quick Ratio: 6.48%
Misc:- Average Volume: 69,311 shs.
- Beta: 0.84
- Short Ratio: 6.37
Frequently Asked Questions for Assembly Biosciences (NASDAQ:ASMB)
What is Assembly Biosciences' stock symbol?
Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."
How were Assembly Biosciences' earnings last quarter?
Assembly Biosciences, Inc. (NASDAQ:ASMB) released its quarterly earnings results on Monday, November, 17th. The company reported ($1.33) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.84. View Assembly Biosciences' Earnings History.
Where is Assembly Biosciences' stock going? Where will Assembly Biosciences' stock price be in 2017?
1 brokerages have issued 1-year target prices for Assembly Biosciences' shares. Their predictions range from $35.00 to $35.00. On average, they expect Assembly Biosciences' share price to reach $35.00 in the next year. View Analyst Ratings for Assembly Biosciences.
Who are some of Assembly Biosciences' key competitors?
Who are Assembly Biosciences' key executives?
Assembly Biosciences' management team includes the folowing people:
- Derek A. Small, President, Chief Executive Officer, Director
- David J. Barrett CPA,, Chief Financial Officer, Chief Operating Officer
- Uri Lopatin M.D., Vice President - Research & Development, Chief Medical Officer
- William R. Ringo, Independent Non-Executive Chairman of the Board
- Alan James Lewis Ph.D., Director
- Anthony E. Altig, Independent Director
- Mark Auerbach CPA,, Independent Director
- Richard DiMarchi, Independent Director
How do I buy Assembly Biosciences stock?
Shares of Assembly Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Assembly Biosciences' stock price today?
One share of Assembly Biosciences stock can currently be purchased for approximately $31.24.
MarketBeat Community Rating for Assembly Biosciences (NASDAQ ASMB)MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Assembly Biosciences (NASDAQ:ASMB) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $35.00 (12.04% upside) |
Consensus Price Target History for Assembly Biosciences (NASDAQ:ASMB)
Analysts' Ratings History for Assembly Biosciences (NASDAQ:ASMB)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/17/2017 | Chardan Capital | Reiterated Rating | Buy | | Medium |  |
| 8/19/2016 | William Blair | Initiated Coverage | Market Perform -> Outperform | | N/A | |
(Data available from 10/20/2015 forward)
Earnings History for Assembly Biosciences (NASDAQ:ASMB)Earnings History by Quarter for Assembly Biosciences (NASDAQ ASMB)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/17/2014 | Q3 2014 | ($0.49) | ($1.33) | | | View | N/A | |
| 4/2/2014 | | ($0.28) | ($0.29) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Assembly Biosciences (NASDAQ:ASMB)2017 EPS Consensus Estimate: ($2.63)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.03) | ($0.03) | ($0.03) |
| Q2 2017 | 1 | ($0.79) | ($0.79) | ($0.79) |
| Q3 2017 | 1 | ($0.88) | ($0.88) | ($0.88) |
| Q4 2017 | 1 | ($0.93) | ($0.93) | ($0.93) |
(Data provided by Zacks Investment Research)
Dividend History for Assembly Biosciences (NASDAQ:ASMB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Assembly Biosciences (NASDAQ:ASMB)Insider Ownership Percentage: 19.60%
Institutional Ownership Percentage: 72.27%
Insider Trades by Quarter for Assembly Biosciences (NASDAQ:ASMB)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/16/2017 | William R Ringo | Director | Sell | 1,000 | $33.70 | $33,700.00 | |
| 2/11/2016 | Derek A. Small | CEO | Buy | 10,000 | $5.53 | $55,300.00 | |
| 5/27/2014 | Russell H Ellison | CEO | Buy | 13,000 | $0.92 | $11,960.00 | |
| 5/23/2014 | David Jonathan Barrett | CFO | Buy | 6,980 | $0.86 | $6,002.80 | |
| 5/23/2014 | Russell H Ellison | CEO | Buy | 20,000 | $0.91 | $18,200.00 | |
| 5/21/2014 | Russell Ellison | CEO | Buy | 10,000 | $0.87 | $8,700.00 | |
| 5/20/2014 | David Jonathan Barrett | CFO | Buy | 40,000 | $0.88 | $35,200.00 | |
| 2/5/2013 | Russell H Ellison | CEO | Buy | 15,000 | $2.55 | $38,250.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Assembly Biosciences (NASDAQ:ASMB)
Latest Headlines for Assembly Biosciences (NASDAQ:ASMB)
| Source: |
|
| Date | Headline |
|---|
 | William R. Ringo Sells 1,000 Shares of Assembly Biosciences, Inc. (ASMB) Stock
www.americanbankingnews.com - October 17 at 8:18 PM |
 | Commit To Purchase Assembly Biosciences At $25, Earn 15.7% Annualized Using Options
www.thestreet.com - October 13 at 9:12 PM |
| Check-Cap (CHEK) & Assembly Biosciences (ASMB) Head-To-Head Comparison
www.americanbankingnews.com - October 12 at 2:26 AM |
| Assembly Biosciences, Inc. (ASMB) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - October 10 at 5:46 PM |
| Reviewing Assembly Biosciences (ASMB) & Its Competitors
www.americanbankingnews.com - October 4 at 2:10 AM |
 | Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development
finance.yahoo.com - October 2 at 3:59 PM |
| Assembly Biosciences Announces 2017 AASLD Presentations
finance.yahoo.com - October 2 at 3:59 PM |
| Analyzing Assembly Biosciences (ASMB) and Its Competitors
www.americanbankingnews.com - October 1 at 4:38 PM |
| Head-To-Head Contrast: Assembly Biosciences (ASMB) & Its Peers
www.americanbankingnews.com - October 1 at 6:24 AM |
 | Assembly Biosciences (ASMB) Presents At Cambridge Healthtech Institute's 15th Annual Discovery On Target - Slideshow
seekingalpha.com - September 28 at 4:33 PM |
| Analyzing Assembly Biosciences (ASMB) & Its Rivals
www.americanbankingnews.com - September 28 at 8:28 AM |
 | Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development - GlobeNewswire (press release)
globenewswire.com - September 28 at 12:56 AM |
| Head-To-Head Comparison: Assembly Biosciences (ASMB) and Its Rivals
www.americanbankingnews.com - September 27 at 4:32 PM |
| Assembly Biosciences (ASMB) vs. Its Peers Critical Survey
www.americanbankingnews.com - September 26 at 2:08 PM |
| Contrasting Assembly Biosciences (ASMB) & The Competition
www.americanbankingnews.com - September 24 at 10:08 PM |
| Critical Contrast: Assembly Biosciences (ASMB) vs. Its Rivals
www.americanbankingnews.com - September 20 at 8:08 AM |
| Assembly Biosciences, Inc. (ASMB) Earns "Buy" Rating from Chardan Capital
www.americanbankingnews.com - September 20 at 6:26 AM |
| Contrasting Assembly Biosciences (ASMB) and Its Competitors
www.americanbankingnews.com - September 17 at 10:16 AM |
| DARA Biosciences (DARA) & Assembly Biosciences (ASMB) Head to Head Review
www.americanbankingnews.com - September 16 at 12:24 PM |
| Contrasting Assembly Biosciences (ASMB) and Aimmune Therapeutics (AIMT)
www.americanbankingnews.com - September 4 at 4:28 AM |
| Contrasting Assembly Biosciences (ASMB) & Supernus Pharmaceuticals (SUPN)
www.americanbankingnews.com - August 21 at 10:26 AM |
| Assembly Biosciences, Inc. – Value Analysis (NASDAQ:ASMB) : August 15, 2017
finance.yahoo.com - August 15 at 10:08 PM |
| Assembly Biosciences, Inc. (NASDAQ:ASMB) Forecasted to Earn Q3 2017 Earnings of ($0.88) Per Share
www.americanbankingnews.com - August 14 at 3:36 AM |
| Analyzing Rockwell Medical (RMTI) and Assembly Biosciences (NASDAQ:ASMB)
www.americanbankingnews.com - August 9 at 10:26 AM |
| Reviewing Assembly Biosciences (ASMB) & Supernus Pharmaceuticals (SUPN)
www.americanbankingnews.com - August 6 at 8:22 PM |
| Assembly Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : ASMB-US : August 2, 2017
finance.yahoo.com - August 2 at 4:54 PM |
| Assembly Biosciences, Inc. (ASMB) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - August 2 at 7:18 AM |
| Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - July 28 at 5:19 PM |
| Head to Head Contrast: TherapeuticsMD (TXMD) vs. Assembly Biosciences (ASMB)
www.americanbankingnews.com - July 19 at 8:25 AM |
| Assembly Biosciences (ASMB) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 4:23 PM |
 | Assembly Biosciences (ASMB) Completes Dose Ranging Portion of Phase 1a/1b Trial of ABI-H0731
www.streetinsider.com - February 17 at 6:29 PM |
| ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
us.rd.yahoo.com - January 10 at 8:43 PM |
 | 8:11 am Assembly Biosciences enters into research, development, collaboration and license agreement with Allergan (AGN); Allergan to make upfront payment of $50 mln
us.rd.yahoo.com - January 10 at 3:42 PM |
| ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure,
biz.yahoo.com - January 10 at 3:42 PM |
| Allergan (AGN) Enters Licensing Agreement with Assembly Biosciences (ASMB) to Obtain Worldwide Rights to GI Programs
www.streetinsider.com - January 9 at 4:29 PM |
 | AGN Stock Is Preparing For Battle (AGN)
www.investopedia.com - January 9 at 4:29 PM |
| ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
biz.yahoo.com - December 9 at 8:43 PM |
| ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - December 6 at 12:37 PM |
| Assembly Biosciences (ASMB) Commences ABI-H0731 Phase 1 as HBV Treatment
www.streetinsider.com - November 10 at 2:05 PM |
 | Assembly Biosciences (ASMB) Worth a Look: Stock Up 7.3%
www.zacks.com - October 17 at 8:26 AM |
| ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - September 2 at 8:19 AM |
| ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
biz.yahoo.com - June 6 at 4:02 PM |
| ASSEMBLY BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 11 at 4:04 PM |
| Assembly Biosciences to Webcast Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - February 19 at 2:59 PM |
Assembly Biosciences (ASMB) Chart for Friday, October, 20, 2017
